Foamix Pharmaceuticals Ltd.’s (FOMX) New Drug Application for FMX101 Minocycline Foam awaits the FDA decision on October 20, 2019.FMX101 Minocycline Foam is proposed for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older.The antibiotic Minocycline is widely prescribed to treat acne, and is currently available as tablets or capsules. Foamix Pharma’s FMX101 is a topical foam formulation of Minocycline.If approved, peak sales of the drug could be between $200 million to $300 million, according to analysts.FOMX closed Friday’s (Sep.27, 2019) trading at $3.07, down 2.5%.